PENT COOPERATION TREC

From the

I. TRNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

DESHMUKH, Jay R. RANBAXY LABORATORIES LIMITED 600 College Road East, Suite 2100 Princeton, New Jersey 08540 ETATS-UNIS D'AMERIQUE PC PERRIMENT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

IMPORTANT NOTIFICATION

Date of mailing

(day/month/year)

28.10.2004

Applicant's or agent's file reference

RLL-273WO

International filing date (day/month/year)

Priority date (day/month/year)

PCT/IB 03/02817

International application No.

16.07.2003

16.07.2002

Applicant

RANBAXY LABORATORIES LIMITED et al.

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:

)

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 **Authorized Officer**

Senkel, H

Tel. +49 89 2399-8071



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference RLL-273WO	FOR FURTHER ACTION	ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)						
International application No. PCT/IB 03/02817	International filing date (day/mor	th/year) Priority date (day/month/year) 16.07.2002						
International Patent Classification (IPC) or A61K31/43	both national classification and IPC							
Applicant RANBAXY LABORATORIES LIMITED et al.								
This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.								
2. This REPORT consists of a tota	. This REPORT consists of a total of 4 sheets, including this cover sheet.							
been amended and are the	This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).							
These annexes consist of a tota	These annexes consist of a total of sheets.							
This report contains indications	relating to the following items:							
I ⊠ Basis of the opinion	Basis of the opinion							
II Priority								
III Non-establishment o	f opinion with regard to novelty, i	nventive step and industrial applicability						
IV Lack of unity of inver	☐ Lack of unity of invention							
	Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							
VI Certain documents c	ited							
VII Certain defects in the	international application							
VIII Certain observations	on the international application							
Date of submission of the demand	Date of	completion of this report						
13.02.2004	28.10	2004						
Name and mailing address of the internation	nal Authori	zed Officer						
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523 Fax: +49 89 2399 - 4465		, M one No. +49 89 2399-8473						

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/IB 03/02817

 Bas 	is of	the	rep	ort
-------------------------	-------	-----	-----	-----

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

	De	scription, Pages					
	1-1	0	as originally filed				
	01-	San a Mariantana					
		ims, Numbers					
	1-7	6	as originally filed				
2.	Wit lan	h regard to the langu guage in which the int	age, all the elements marked above were available or furnished to this Authority in the ternational application was filed, unless otherwise indicated under this item.				
	These elements were available or furnished to this Authority in the following language: , which is:						
		the language of a tra	anslation furnished for the purposes of the international search (under Rule 23.1(b)).				
		the language of publication of the international application (under Rule 48.3(b)).					
		the language of a tra Rule 55.2 and/or 55.	anslation furnished for the purposes of international preliminary examination (under 3).				
3.	 With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing: 						
		contained in the international application in written form.					
		Ifiled together with the international application in computer readable form.					
		I furnished subsequently to this Authority in written form.					
		furnished subsequently to this Authority in computer readable form.					
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.					
		The statement that the listing has been furnit	he information recorded in computer readable form is identical to the written sequence ished.				
4.	The	amendments have resulted in the cancellation of:					
		the description,	pages:				
		the claims,	Nos.:				
		the drawings,	sheets:				
5.		This report has been been considered to g	established as if (some of) the amendments had not been made, since they have go beyond the disclosure as filed (Rule 70.2(c)).				
		(Any replacement sh report.)	neet containing such amendments must be referred to under item 1 and annexed to this				
6.	Add	litional observations, i	f necessary:				

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/IB 03/02817

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

12, 17-19.

22,23,28,30,31,37-39,49,52,55,56,63,65,66,68,73-75

No: Claims

1-

11,13-16,20,

21,24-

27,29,32-36,40-48,50,51,53,54,57-62,64,67,69-72,76

Inventive step (IS)

Yes: Claims

12,17-19,22,23,30,31,37-39,52,55,56,65,66,68,73-75

No: Claims

1-11,13-16,20,

21,24-29,32-36,40-49,50,51,53,54,57-64,67,69-72,76

Industrial applicability (IA)

Yes: Claims

1-76

No: Claims

2. Citations and explanations

see separate sheet

D1: WO 98 35672 A (SMITHKLINE BEECHAM) 20 August 1998 (1998-08-20)

D2: WO 92 19227 A (SMITHKLINE BEECHAM) 12 November 1992 (1992-11-

12)

Document D1 already describes a water dispersable tablet formulation comprising 1) amoxicillin as the β -lactam antibiotic, clavulanate as the β -lactamase inhibitor and a disintegrating agent which is used intragranularly and extragranularly (see page 5, line 24, to page 6, line 35, and page 12, lines 20 to 26, the examples and the claims).

In addition, also document D2 discloses such compositions with or without clavulanate (see the examples in particular).

Therefore the subject-matter of claims 1 to 11, 13 to 16, 20, 21, 24 to 27, 29, 32 to 36, 40 to 48, 50, 51, 53, 54, 57 to 62, 64, 67, 69 to 72 and 76 is not novel (Article 33 (2) PCT).

The subject-matter of claims 28, 49 and 63 merely consists in an optimization of 2) the contents of the filler.

However, the routine experimentation to optimize the required amounts of ingredients of known compositions for a known use falls within the normal capacity of the average skilled person so that the subject-matter of these claims does not involve an inventive step (Article 33 (3) PCT).

The remainder of the claims is not obvious in view of the documents cited in the 3) Search Report.

Therefore the subject-matter of these claims involves an inventive step.